December 2025 - Page 4 of 13

Release – NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer’s Phase 2 Study

Posted on December 22, 2025December 22, 2025 by slightbourne@noblecapitalmarkets.com

CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today reported completion of the safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC combination in Alzheimer’s disease.

The safety analysis indicated a favorable tolerability profile for PrimeC. No serious adverse events were reported, and no new or unexpected safety signals were identified.

As an exploratory proof-of-concept study, clinical outcome measures are descriptive by design. NeuroSense will analyze clinical observations alongside biomarker data to enable a more comprehensive interpretation of the clinical observations, with results expected in the first quarter of 2026.

About Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding the timing of the reporting of additional data from the study of PrimeC in Alzheimer’s disease, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

Gold and Silver Surge to All-Time Highs as Geopolitical Risks Reshape Global Markets

Posted on December 22, 2025December 22, 2025 by slightbourne@noblecapitalmarkets.com

Gold and silver have surged to historic highs, underscoring a powerful shift in global investor sentiment as geopolitical tensions intensify and confidence in traditional financial systems continues to erode. The rally marks one of the strongest performances for precious metals in more than four decades, driven by a potent mix of political uncertainty, monetary policy expectations, and structural demand.

Gold briefly climbed above $4,400 per ounce, eclipsing its previous record set earlier this year, while silver pushed toward the $70 level, a price not seen in modern trading history. These moves are not isolated technical breakouts; they reflect a broader re-pricing of risk across global markets as investors seek safety amid escalating international conflicts and economic uncertainty.

Geopolitical flashpoints have multiplied in recent months. The United States has intensified economic and energy pressure on Venezuela, while the conflict between Russia and Ukraine has expanded beyond traditional battlefields into global shipping lanes. Meanwhile, rising tensions between major world powers — including strained U.S.–China relations and growing unease in parts of Asia — have added to a climate of persistent instability. Historically, such environments have favored hard assets, and this cycle is proving no different.

At the same time, expectations for looser monetary policy have reinforced the rally. Markets are increasingly pricing in multiple U.S. interest rate cuts in 2026 as economic data shows signs of cooling inflation and slower job growth. Lower interest rates tend to weaken the opportunity cost of holding non-yielding assets like gold and silver, making them more attractive relative to bonds and cash.

Central banks have played a critical role in underpinning gold’s rise. Official sector purchases remain elevated as nations diversify reserves away from the U.S. dollar and reduce exposure to sovereign debt. This trend has been amplified by political rhetoric that has raised concerns about the long-term independence of central banks and the sustainability of ballooning government deficits.

Investor demand has followed suit. Gold-backed exchange-traded funds have recorded steady inflows, while silver has benefited from speculative activity and lingering supply disruptions following a historic short squeeze earlier in the year. Industrial demand — particularly for silver and platinum in energy, technology, and manufacturing — has added another layer of support.

Beyond traditional investors, new participants are entering the precious metals market. Corporate treasuries, alternative asset managers, and even stablecoin issuers are increasingly using physical metals as balance-sheet hedges, broadening the capital base supporting prices and making demand more resilient.

Looking ahead, major financial institutions remain bullish. Several banks project gold prices continuing higher into 2026, citing constrained physical supply, sustained central-bank buying, and ongoing geopolitical risk. While short-term volatility is inevitable, the underlying drivers of the rally appear firmly intact.

In an era defined by geopolitical fragmentation, monetary uncertainty, and rising systemic risk, gold and silver are once again fulfilling their historical role: not just as commodities, but as financial insurance in an increasingly unpredictable world.

Bit Digital (BTBT) – WhiteFiber Snags a New Contract

Posted on December 22, 2025December 22, 2025 by slightbourne@noblecapitalmarkets.com

Monday, December 22, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Contract. Late last week, Bit Digital’s key investment, WhiteFiber, announced its Enovum Data Centers Corp. subsidiary has executed a long-term colocation agreement with Nscale Global Holdings, an AI infrastructure and cloud services provider serving enterprise and public sector customers. The contract represents approximately $865 million in contracted revenue over the initial 10-year term.

NC-1. The agreement secures the first 40 megawatt delivery of critical IT load at WhiteFiber’s flagship NC-1 data center campus in Madison, North Carolina. The contract includes contractual annual rate escalators and required non-recurring installation services, but excludes electricity and certain other costs passed through to the customer. Nscale is deploying the capacity to power the AI infrastructure of leading global investment grade technology customers.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

AZZ (AZZ) – Updating Estimates; Maintaining Positive Outlook and Outperform Rating

Posted on December 22, 2025December 22, 2025 by slightbourne@noblecapitalmarkets.com

Monday, December 22, 2025

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Updating estimates. While our fiscal year 2026 estimates are unchanged,we have increased our fiscal year 2027 adjusted EBITDA and EPS estimates to $387.8 million and $6.45 from $386.2 million and $6.41, respectively. Our estimates reflect modestly higher revenue for the Precoat Metals segment and lower interest expense relative to prior estimates. We have increased our FY 2027 capital expenditure estimate to $80 million from $70 million to reflect greater reinvestment in the base business, including capacity expansions. Our estimates do not reflect acquisitions until they are announced.

The benefits of a strong cash flow profile. After having significantly reduced its debt profile, AZZ continues to prioritize strategic bolt-on acquisitions as a central component of its growth strategy. In fiscal 2026 and beyond, capital allocation priorities have shifted to strategic M&A, high-return organic investments, and return of capital through growing dividends and share repurchases. We anticipate an annual increase to the quarterly dividend following the lead established during the first quarter of FY 2026. Based on its cash flow profile, we think share repurchases may go beyond a level that simply offsets dilution from management incentive compensation.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Alphabet Deepens AI Strategy With $4.75 Billion Acquisition of Clean Energy Developer Intersect

Posted on December 22, 2025December 22, 2025 by slightbourne@noblecapitalmarkets.com

Alphabet is making a decisive move to secure the energy backbone of its artificial intelligence ambitions. The Google parent announced it will acquire clean energy developer Intersect in a $4.75 billion cash deal, including assumed debt, underscoring how access to power has become a strategic priority in the global AI race.

The acquisition comes as Big Tech companies pour billions into expanding computing capacity to support generative AI models, cloud services, and data centers — all of which require enormous and reliable amounts of electricity. As U.S. power grids strain to keep pace with surging demand, technology firms are increasingly turning upstream, investing directly in energy generation rather than relying solely on utilities.

Intersect brings scale that few developers can match. The company has roughly $15 billion in assets that are either operating or under construction, with projects expected to deliver about 10.8 gigawatts of power by 2028. That capacity is more than twenty times the electricity generated by the Hoover Dam, highlighting the magnitude of energy now required to sustain AI-driven growth.

Under the agreement, Alphabet will acquire Intersect’s energy and data center projects that are currently under development or construction. These assets are designed to support large-scale computing infrastructure, aligning closely with Google’s expanding network of U.S. data centers. Intersect’s operations will remain separate from Alphabet, preserving operational independence while strategically supporting Google’s long-term power needs.

Notably, Intersect’s existing operating assets in Texas and its operating and in-development projects in California will not be included in the deal. Those assets will continue as an independent business backed by existing investors. Among them is Quantum, a clean energy storage system in Texas built directly alongside a Google data center campus — a model increasingly favored by hyperscalers seeking to pair computing facilities with on-site or adjacent power sources.

The deal builds on Alphabet’s broader push into energy partnerships. Earlier this month, NextEra Energy expanded its collaboration with Google Cloud to develop new energy supplies across the U.S. Together, these moves signal a shift in how tech giants approach infrastructure: energy security is no longer a background consideration, but a core component of competitive advantage.

For Alphabet, the acquisition also reinforces its commitment to clean energy. As AI workloads expand, the environmental footprint of data centers has drawn scrutiny from regulators and investors alike. By investing directly in renewable generation and energy storage, Alphabet aims to mitigate emissions while insulating itself from grid bottlenecks, price volatility, and regulatory risk.

Intersect will also explore emerging energy technologies to diversify supply, according to Alphabet, positioning the company to adapt as AI-driven electricity demand continues to grow. This forward-looking approach reflects a broader industry trend, where control over power generation is becoming just as critical as control over chips, data, and algorithms.

Ultimately, Alphabet’s purchase of Intersect highlights a defining reality of the AI era: the battle for intelligence is also a battle for energy. As demand accelerates, companies that can secure scalable, reliable, and clean power may hold a decisive edge in shaping the future of technology.

Release – GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering

Posted on December 19, 2025December 19, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GOVX

Atlanta, GA, December 19, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into definitive securities purchase agreements with several institutional and individual investors for the purchase and sale of approximately 13.2 million units, each comprised of one share of the Company’s common stock and warrants, as described below, to purchase shares of the Company’s common stock, at a price of $0.245 per unit in a public offering. The Company will issue warrants to purchase up to approximately 26.5 million shares of common stock. The warrants will have an exercise price of $0.245 per share, will be exercisable immediately following the date of issuance and will have a term of five years following the date of issuance.

Roth Capital Partners is acting as the exclusive placement agent for the offering.

The gross proceeds to the Company from this offering are expected to be approximately $3.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The closing of the offering is expected to occur on or about December 22, 2025, subject to the satisfaction of customary closing conditions.

The shares in the offering described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-292127) previously filed with the Securities and Exchange Commission (the ‘SEC’) and declared effective by the SEC on December 19, 2025. The offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement, relating to the offering that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Roth Capital Partners, LLC at 888 San Clemente Drive, Newport Beach CA 92660, by phone at (800) 678-9147 or by accessing the SEC’s website, www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

info@geovax.com

678-384-7220

Media Contact:

Jessica Starman

media@geovax.com

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Leadership in Rare Diseases

Posted on December 19, 2025December 19, 2025 by slightbourne@noblecapitalmarkets.com

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced it has entered into a definitive agreement to acquire Amicus Therapeutics (Nasdaq: FOLD) in an all-cash transaction valued at approximately $4.8 billion. Under the terms of the deal, BioMarin will acquire Amicus for $14.50 per share, representing a significant premium to Amicus’ recent trading levels. The transaction is expected to close in the second quarter of 2026, subject to regulatory approvals and Amicus shareholder approval.

The acquisition significantly expands BioMarin’s presence in the rare disease market by adding two marketed, high-growth therapies to its commercial portfolio. Amicus brings Galafold® (migalastat), an oral therapy for Fabry disease, and Pombiliti® (cipaglucosidase alfa-atga) in combination with Opfolda® (miglustat), a next-generation treatment for Pompe disease. Together, these products generated $599 million in revenue over the past four quarters, immediately strengthening BioMarin’s top-line growth profile.

From a strategic standpoint, the transaction deepens BioMarin’s focus on lysosomal storage disorders, an area where the company already has established expertise and commercial infrastructure. The addition of Amicus’ therapies is expected to accelerate BioMarin’s long-term revenue growth rate through 2030 and beyond, while diversifying its enzyme therapies business unit. BioMarin also plans to leverage its global commercial footprint to expand access to Galafold and Pombiliti + Opfolda in additional international markets.

The deal carries favorable financial implications for BioMarin shareholders. Management expects the acquisition to be accretive to non-GAAP diluted earnings per share within the first 12 months following closing and substantially accretive beginning in 2027. BioMarin intends to finance the transaction using a combination of existing cash and approximately $3.7 billion in new debt financing, with no equity issuance required. The company has stated that it remains committed to deleveraging, targeting gross leverage below 2.5x within two years after closing.

Importantly, a key overhang related to Galafold’s U.S. intellectual property has been resolved ahead of the acquisition. Amicus has settled ongoing patent litigation with generic challengers, securing U.S. exclusivity for Galafold until January 2037, barring limited customary exceptions. This resolution enhances revenue visibility and strengthens the long-term value of the Fabry franchise within BioMarin’s portfolio.

Beyond marketed products, Amicus also contributes pipeline optionality. The company holds U.S. rights to DMX-200, a Phase 3 investigational therapy for focal segmental glomerulosclerosis (FSGS), a rare and often fatal kidney disease. While not central to the acquisition thesis, the asset provides additional upside potential.

Overall, the acquisition underscores BioMarin’s capital allocation strategy of deploying its strong balance sheet to acquire de-risked, revenue-generating assets that align with its core rare disease focus. With immediate revenue contribution, improved earnings power, and expanded global reach, the Amicus transaction positions BioMarin to strengthen its leadership in rare diseases while delivering long-term shareholder value.

Greenwich LifeSciences, Inc. (GLSI) – FLAMINGO-01 Open-Label Arm Reports Preliminary Results and Reaches An Important Milestone

Posted on December 19, 2025December 19, 2025 by slightbourne@noblecapitalmarkets.com

Friday, December 19, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Data Reported From the Open-Label Arm Of The FLAMINGO Trial Greenwich LifeSciences announced preliminary Phase 3 results from the open-label, non-HLA-A*02 arm of its FLAMINGO-01 trial. The data showed a reduction in breast cancer recurrence rates of about 80% for patients that completed the primary vaccination series (PIS) ofGLSI-100. In addition, the first patient has completed the full 3-year treatment.

FLAMINGO0-01 Divides Patients By Immune Classification. The FLAMINGO-01 trial divides patients by their HLA types, a system of classifying a patient’s immune response. Patients with the most common HLA type, HLA-A*02, have enter one of the double-blind placebo-controlled arms of the trial. About 250 patients with other HLA types have been entered into an open-label portion, referred to as non-HLA-A*02.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Saga Communications (SGA) – A Shareholder First Centric Company

Posted on December 19, 2025December 19, 2025 by slightbourne@noblecapitalmarkets.com

Friday, December 19, 2025

Saga Communications, Inc. is a broadcast company whose business is primarily devoted to acquiring, developing and operating radio stations. Saga currently owns or operates broadcast properties in 27 markets, including 79 FM and 33 AM radio stations. Saga’s strategy is to operate top billing radio stations in mid sized markets, defined as markets ranked (by market revenues) from 20 to 200. Saga’s radio stations employ a myriad of programming formats, including Active Rock, Adult Album Alternative, Adult Contemporary, Country, Classic Country, Classic Hits, Classic Rock, Contemporary Hits Radio, News/Talk, Oldies and Urban Contemporary. In operating its stations, Saga concentrates on the development of strong decentralized local management, which is responsible for the day-to-day operations of the stations in their market area and is compensated based on their financial performance as well as other performance factors that are deemed to effect the long-term ability of the stations to achieve financial objectives. Saga began operations in 1986 and became a publicly traded company in December 1992. The stock trades on NASDAQ under the ticker symbol “SGA”.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Share repurchase. On December 15, the company announced the completion of a sizeable share buyback that was conducted through a privately negotiated transaction. Notably, the company repurchased 184,215 shares for approximately $2.1 million, or $11.50 per share, which represented roughly 2.8% of the 6,556,621 shares outstanding as of December 11.

Tower sale. Importantly, the share buyback was largely expected following the sale of 22 tower sites for approximately $10.7 million in late October. Net proceeds of $8.7 million were earmarked to be used for share repurchases.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Oracle Shares Surge as Cloud Giant Joins Investor Group to Run TikTok’s U.S. Business

Posted on December 19, 2025December 19, 2025 by slightbourne@noblecapitalmarkets.com

Oracle (ORCL) shares jumped roughly 8% Friday after the cloud computing company confirmed it will join a group of investors set to lead TikTok’s U.S. operations, a move that eases national security concerns and removes a major overhang for the popular social media platform. The rally marked a sharp reversal for Oracle stock, which has faced heightened volatility in recent weeks amid broader uncertainty around artificial intelligence infrastructure spending.

According to an internal memo sent to employees, TikTok’s U.S. business will be operated through a new joint venture that includes Oracle, private equity firm Silver Lake, and Abu Dhabi-based investment group MGX. The deal is expected to close on January 22 and is designed to comply with U.S. legislation requiring ByteDance, TikTok’s China-based parent company, to divest control of the app’s U.S. operations.

The agreement effectively prevents a potential shutdown or ban of TikTok in the United States, which had loomed after President Joe Biden signed legislation mandating divestiture over national security concerns. President Donald Trump previously extended deadlines for a deal multiple times and approved a potential framework through an executive order earlier this year, setting the stage for the current agreement.

Under the terms outlined in the memo, Oracle will play a critical role in ensuring compliance with U.S. national security requirements. The company will be responsible for auditing and validating that TikTok adheres to agreed-upon safeguards, including how sensitive U.S. user data is handled and stored. Oracle’s cloud infrastructure will house this data, reinforcing the company’s position as a trusted enterprise technology provider.

While China has not formally confirmed the transaction, reports from Chinese state media suggest the deal is expected to move forward. Commentary cited by CNBC indicates the structure aligns with Chinese regulations and does not constitute a sale of TikTok’s core recommendation algorithm, a key sticking point in past negotiations.

Investors responded positively to the announcement, viewing it as both a strategic win and a stabilizing development for Oracle. In a note to clients, Evercore ISI described the move as a “nice win” for the cloud provider, highlighting potential upside as the market reassesses Oracle’s longer-term growth outlook. The firm suggested that the recent pullback in shares may present an attractive entry point for investors with a six- to twelve-month time horizon.

The TikTok news arrives after a turbulent period for Oracle stock. Shares have been pressured by concerns over the sustainability of the artificial intelligence trade and the capital intensity required to build out large-scale AI data centers. Earlier this week, Oracle shares slid following reports that negotiations over a $10 billion data center deal with Blue Owl Capital had stalled, amplifying investor anxiety about funding risks tied to AI infrastructure expansion.

Despite Friday’s rally, Oracle stock remains down more than 20% over the past month, reflecting the market’s reassessment of high-multiple tech names. Year to date, however, shares are still up about 8%, underscoring the company’s ability to rebound when strategic clarity emerges.

Oracle’s involvement in TikTok’s U.S. operations reinforces its growing role at the intersection of cloud computing, data security, and large-scale digital platforms. While questions around AI spending persist, the TikTok partnership offers a timely boost to sentiment and highlights Oracle’s relevance in high-profile, mission-critical technology deals.

Release – Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

Posted on December 18, 2025December 18, 2025 by aweinsoff@channelchek.com

Research News and Market Data on NTRB

The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum Technology

December 18, 2025 08:00 ET | Source: Nutriband Inc.

ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) (“Nutriband” or the “Company”), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent (“LOI”) with the Qvanta Group of Companies.

The Qvanta Group comprises Qvanta LLC and its subsidiaries, Qvanta Foundry LLC and Qvanta Capital LLC (collectively, “Qvanta”). Qvanta is a U.S.-based advanced technology organization developing the BigΔx Quantum Defense Fabric, an integrated quantum-AI cybersecurity and computing platform designed to support enterprise, government, and high-security research environments.

The announcement comes amid heightened federal focus on three converging national priorities. On December 15, 2025 President Trump signed an Executive Order designating illicit fentanyl as a Weapon of Mass Destruction, recognizing the substance as a direct threat to U.S. national security (https://www.whitehouse.gov/presidential-actions/2025/12/designating-fentanyl-as-a-weapon-of-mass-destruction/).

In parallel, the Administration’s America’s AI Action Plan emphasizes accelerating the responsible adoption of artificial intelligence across regulated sectors, including healthcare and pharmaceuticals (https://www.whitehouse.gov/articles/2025/07/white-house-unveils-americas-ai-action-plan/).

Additionally, the Genesis Mission Executive Order establishes quantum information science as a national priority, underscoring the strategic importance of advanced computing technologies in addressing complex national challenges (https://www.whitehouse.gov/presidential-actions/2025/11/launching-the-genesis-mission/).

Nutriband believes that Qvanta’s quantum-AI simulation capabilities, secure high-performance computing infrastructure, and advanced cybersecurity technologies may provide meaningful support for Nutriband’s research, innovation efforts, and long-term product development initiatives.

Under the LOI, the parties plan to explore potential collaboration areas including secure AI and analytics platforms for regulated pharmaceutical data, cybersecurity and data-integrity frameworks that support abuse-deterrent technologies, and advanced modeling and simulation capabilities enabled by quantum-ready infrastructure. Any discussions would emphasize regulatory compliance, strong data protection, and responsible technology use.

The LOI is non-binding and does not establish a partnership, joint venture, equity investment, licensing arrangement, or other binding commercial relationship. Any future collaboration would be subject to additional technical and regulatory review, due diligence, and the execution of definitive agreements. There can be no assurance that a definitive agreement will be reached or that any transaction will ultimately occur.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ technology directly addresses the fentanyl crisis by incorporating aversive agents into transdermal patches designed to prevent abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The Company’s lead product under development is an abuse-deterrent fentanyl transdermal system, protected by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

Nutriband Inc. (NASDAQ: NTRB) develops transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch incorporating proprietary AVERSA™ technology. For more information, visit www.nutriband.com.

About Qvanta Group of Companies

The Qvanta Group of Companies (https://qvanta.io) develops AI-driven and quantum-ready infrastructure solutions for national security, enterprise resilience, and regulated industries. The group comprises Qvanta LLC (operating entity), Qvanta Foundry LLC (R&D), and Qvanta Capital LLC (investment solutions).

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.

Release – GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA

Posted on December 18, 2025December 18, 2025 by aweinsoff@channelchek.com

Research News and Market Data on GOVX

EMA Concurrence Enables Acceleration Toward Phase 3 Initiation and Represents a Major Milestone on GeoVax’s Path to Commercialization

ATLANTA, GA – December 18, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that it has received formal Scientific Advice (SA) from the European Medicines Agency (EMA) confirming regulatory alignment on the Company’s proposed pivotal Phase 3 immunobridging trial design for GEO-MVA, its Modified Vaccinia Ankara (MVA)-based vaccine candidate for the prevention of Mpox and smallpox.

The EMA’s feedback concurs with GeoVax’s proposed strategy to evaluate GEO-MVA through a single, pivotal Phase 3 immuno-bridging study versus the approved MVA vaccine, Imvanex®, and supports the Company’s plan to proceed directly into this trial without the need for additional Phase 1 or Phase 2 clinical studies. Receipt of this formal Scientific Advice represents a significant regulatory milestone and enables GeoVax to accelerate operational planning toward implementation and initiation of the Phase 3 program, currently projected to begin in the second half of 2026.

“This formal Scientific Advice from EMA represents a pivotal step forward for GEO-MVA and meaningfully de-risks our regulatory path in Europe,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “EMA’s concurrence positions GeoVax to move efficiently toward a single, registrational Phase 3 study. This is a major milestone on our path toward commercialization.”

The Scientific Advice confirms that non-inferiority immunogenicity endpoints are acceptable to support a future Marketing Authorization Application (MAA) and that GeoVax’s proposed clinical safety database is sufficient to support registration, assuming successful trial outcomes. Importantly, EMA’s feedback provides clarity and confidence across proposed clinical and quality dimensions, allowing the Company to focus on execution rather than redesign of its development strategy.

The receipt of this advice follows GeoVax’s previous announcement of favorable preliminary EMA guidance announced in June 2025 and marks the transition from regulatory alignment to regulatory execution. Together, these milestones substantially strengthen GEO-MVA’s development profile and reinforce its potential role in expanding global Mpox and smallpox vaccine supply beyond the current single-supplier paradigm.

“With formal EMA Scientific Advice now in hand, GEO-MVA moves from a conceptual regulatory pathway to a clearly defined and executable development plan,” Dodd added. “As global health authorities continue to emphasize preparedness, resilience, and diversification of vaccine supply, we believe GEO-MVA is well positioned to play an important role.”

About GEO-MVA

GEO-MVA is GeoVax’s Modified Vaccinia Ankara (MVA)-based vaccine candidate being developed for the prevention of Mpox and smallpox. GEO-MVA leverages the well-characterized MVA platform and is designed to support both civilian public health needs and broader preparedness objectives.

About GeoVax

Forward-Looking Statements

Company Contact:

info@geovax.com

678-384-7220

Media Contact:

Jessica Starman

media@geovax.com

Release – MariMed Statement on Historic Rescheduling of Cannabis

Posted on December 18, 2025December 18, 2025 by aweinsoff@channelchek.com

Research News and Market Data on MRMD

December 18, 2025 1:52pm EST Download as PDF

NORWOOD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator committed to improving lives every day, issued the following statement from CEO Jon Levine today.

“We commend President Trump and the Trump Administration for reclassifying cannabis as a Schedule III drug. This is the single greatest cannabis reform in US history and will have far-reaching benefits for years to come. Most important, the reclassification means the Federal government officially acknowledges that cannabis has widely accepted medical uses and low abuse potential.

Rescheduling will accelerate accredited medical research into medications derived from cannabis and should result in a significant increase of consumers who will embrace cannabis as a qualified alternative to opioids for chronic pain, sleep, anxiety and other ailments.

Additionally, state-legal cannabis businesses will no longer be subject to the IRS Section 280E tax penalty. Compliant operators like MariMed will finally be taxed like other consumer packaged goods sectors, materially improving profitability and free cash flow.”

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Media Contact:
Zach Galasso
DPA Communications
Email: zach@dpacommunications.com
Phone: (978) 604-5423

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

Source: MariMed Inc.

Released December 18, 2025